Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
News
Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for in
Read more
Report
Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy
Read more
Report
Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City's Life Science Innovation Cluster
Juvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar City Jennings-Brown will drive AI and technology strategy and lead the development of capabilities enab
Read more
Report
Richards interview to Jo Shorthouse
There's still capital out there - it's just coming from new directions. Our CEO, Richard Marshall CBE, shares his insights on the evolving biotech funding landscape and where companies like Juvenescence are finding opportunity amid the VC pullback by forg
Read more
Report
New Medicines for the Healthspan Revolution M42
https://www.youtube.com/watch?v=FKrjMToSbjw
Read more
Report
Demystifying Biotechnology: A Deep Dive into Juvenescence M42
https://www.youtube.com/watch?v=p_GDB_YwAIg
Read more
Report